Thunder Bridge Capital Partners IV, Inc. and Coincheck Group N.V. Announce Closing of Business Combination
Coincheck Group N.V. ordinary shares and warrants to begin trading on Nasdaq on December 11, 2024 as “CNCK” and “CNCKW,” respectively.
Coincheck Group N.V. (“Coincheck”), a Dutch public limited liability company and a holding company of a cryptocurrency trading service company, and Thunder Bridge Capital Partners IV, Inc. (Nasdaq: THCP, THCPU & THCPW) (“Thunder Bridge IV”), a special purpose acquisition company, announced today the consummation of their previously announced business combination. As a result, the ordinary shares and warrants of Coincheck will commence trading on Nasdaq on December 11, 2024 under the new ticker symbols “CNCK” and “CNCKW,” respectively. The business combination was approved at a special meeting of the shareholders of Thunder Bridge IV on December 5, 2024.
“The completion of our business combination with Thunder Bridge IV marks an extraordinary milestone for Coincheck,” said Oki Matsumoto, Representative Executive Officer and Chairman of Monex Group, Inc., and Executive Chairman of Coincheck. “Coincheck was created through the fusion of a robust business foundation built in Japan, combined with the strengths of the U.S. capital markets through the close collaboration of exceptional business and capital markets talent in both Japan and the U.S. We are incredibly proud and excited to become a Nasdaq listed company and for what the future holds for the Coincheck group companies and our shareholders.”
“We are pleased to announce the closing of our merger with the entire Coincheck team,” said Gary Simanson, President and CEO of Thunder Bridge IV. “As a member of the board of directors and CEO of Coincheck, I look forward to partnering with Oki and his team to build one of the preeminent global crypto and Web3 companies in the world.”
Coincheck Group N.V. (“CNCK” and “CNCKW”), is a global holding company, headquartered in the Netherlands, operating in the crypto asset and Web3 domains, and is the parent company of Coincheck, Inc. (“Coincheck Japan”), which operates the regulated crypto asset trading service “Coincheck” in Japan. Coincheck Japan is the leading crypto asset exchange in Japan and is one of the most established and trusted names in crypto. Coincheck Japan has been recognized as Japan’s No.1* most downloaded trading app for five consecutive years. Coincheck is on a mission to “Make Exchange of New Value Easier” by utilizing crypto assets and blockchain technology.
Coincheck Group N.V. is one of only two publicly listed companies on NASDAQ having a crypto asset exchange as its core business. As a newly listed NASDAQ company, and “Your Trusted Global Partner in the Digital World,” Coincheck is well-positioned to further solidify the group’s dominant position in Japan’s crypto asset trading industry and to establish the group as a global player in the crypto and Web3 industry worldwide.
The business combination resulted in gross proceeds of approximately $31.6 million to the combined company, including funds held in a restricted account pursuant to the terms of the previously announced non-redemption agreement, and net of Thunder Bridge IV shareholder redemptions.
J.P. Morgan Securities LLC served as sole financial advisor to Monex Group, Inc., Coincheck Japan’s former direct parent company and now the parent company of Coincheck, in connection with the business combination. Galaxy Digital Partners LLC served as financial advisor to Thunder Bridge IV and Barclays Capital Inc, BTIG, LLC, Cantor Fitzgerald & Co., Inc, Keefe, Bruyette & Woods, Inc., a Stifel Company, and KeyBanc Capital Markets Inc. served as capital markets advisors to Thunder Bridge IV in connection with the business combination. Nelson Mullins Riley & Scarborough LLP, Mori Hamada & Matsumoto, Littler Mendelson P.C. and Allen & Overy LLP served as legal advisors to Thunder Bridge IV and Simpson Thacher & Bartlett LLP, Anderson Mori & Tomotsune, and De Brauw Blackstone Westbroek N.V. served as legal advisors to Coincheck and Monex Group, Inc.
Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about trading, future financial and operating results, plans, objectives, expectations and intentions with respect to future operations, products and services; and other statements identified by words such as “will likely result,” “are expected to,” “will continue,” “is anticipated,” “estimated,” “believe,” “intend,” “plan,” “projection,” “outlook” or words of similar meaning or the negative thereof. These forward-looking statements include, but are not limited to, statements regarding Coincheck’s trading, industry and market sizes, future opportunities for Coincheck , Coincheck Japan and Thunder Bridge IV, Coincheck’s estimated future results and the business combination between Thunder Bridge IV and Coincheck.. Such forward-looking statements are based upon the current beliefs and expectations of our management and are inherently subject to significant business, economic and competitive uncertainties and contingencies, many of which are difficult to predict and generally beyond our control, which could cause actual results or events to differ materially from those presently anticipated including (i) a delay or failure to realize the expected benefits from the business combination, (ii) risks related to disruption of management’s time from ongoing business operations due to the business combination, (iii) changes in the cryptocurrency and digital asset markets in which Coincheck competes, including with respect to its competitive landscape, technology evolution or regulatory changes, (iv) changes in domestic and global general economic conditions, (v) risk that Coincheck may not be able to execute its growth strategies, including identifying and executing acquisitions, (vi) risk that Coincheck may not be able to develop and maintain effective internal controls and (vii) and other risks and uncertainties discussed in Coincheck’s filings with the U.S. Securities and Exchange Commission. Coincheck undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as required by law.
About Coincheck Group N.V.
Coincheck Group N.V. is a Dutch public limited liability company and a holding company of Coincheck, Inc., , which operates the “Coincheck” cryptocurrency trading service, and has achieved the highest number of app downloads in Japan for 5 consecutive years*. With the mission of “Making Exchange of New Value Easier,” Coincheck, Inc. aims to create better services that allow people to feel the value of new exchanges created by cryptocurrencies and blockchain technologies, through the latest technology and advanced security.
*Target: Cryptocurrency trading app in Japan, Period: January 2019-December 2023, Data cooperation: App Tweak
View source version on businesswire.com: https://www.businesswire.com/news/home/20241210703460/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom